Corporate Profile

SBI Biotech Co., Ltd. is a bio-venture firm envisaged and founded by SBI Holdings President & CEO, Mr. Yoshitaka Kitao and Molecular Biologist, Dr. Ken-ichi Arai.

SBI Biotech is

Venture that links latest achievement in life science to state-of-the-art treatment and innovative drug discovery.

Venture that can promote drug development from seed discovery to clinical studies.

Venture that identifies promising drug seeds and develops drug pipelines from the world.

Global venture wherein researchers from Japan, U.S., Israel, China, Korea and the other countries to cooperate across borders.

Corporate Fact Sheet

As of December 31, 2018

Corporate NameSBI Biotech Co., Ltd.
Capital100,000 thousand Yen
Board of Directors
Representative Director, President
Takeshi Irie
Eiji Esashi,PhD
Koji Nakano
Masahiro Kami,PhD
Atsushi Miyajima,PhD
Board of Corporate Auditors
Standing Corporate Auditor
Ichiro Hamamoto
Corporate Auditor
Junji Maruko
Corporate Auditor
Tsunehiko Kuwata
Date of FoundationMarch 30,2001
Head OfficeIzumi Garden Tower 15F
1-6-1 Roppongi, Minato-ku Tokyo 106-6015Map
Telephone:+81-3-6229-0787  Fax:+81-3-3583-2022
Number of shares issued99,672
Principal affiliatesQuark Pharmaceuticals, Inc.
6501Dumbarton Circle, Fremont,California, USA

Origin of Corporate Name

We named our company "SBI Biotech" to indicate our wishes, as the first bio-venture firm in the SBI Group, to contribute to society through commercializing various promising and innovative drug seeds.

sbi biotech logo image

 Back to top